DYNC2I2 and breast cancer: For DYNC2I2 (also known as WDR34), an integrated bioinformatics study shows that high DYNC2I2 mRNA expression is correlated with shorter overall survival and relapse-free survival in breast cancer patients (67), which is consistent with our finding that DYNC2I2 could serve as a risky factor in TNBC.